Trial Profile
A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis, antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have previously received BCG
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 23 Feb 2007 New trial record.